Agenus Inc. (AGEN)
Largest Insider Buys in Sector
AGEN Stock Price History Chart
AGEN Stock Performance
About Agenus Inc.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical …
Insider Activity of Agenus Inc.
Over the last 12 months, insiders at Agenus Inc. have bought $324,050 and sold $0 worth of Agenus Inc. stock.
On average, over the past 5 years, insiders at Agenus Inc. have bought $171,525 and sold $1.46M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ARMEN GARO H (See Remarks) — $648,100.
The last purchase of 500,000 shares for transaction amount of $324,050 was made by ARMEN GARO H (See Remarks) on 2024‑02‑15.
List of Insider Buy and Sell Transactions, Agenus Inc.
| 2024-02-15 | See Remarks | 500,000 0.0915% | $0.65 | $324,050 | -50.38% | |||
| 2023-11-15 | director | 25,000 0.0067% | $0.76 | $19,000 | -20.20% | |||
| 2022-01-06 | Sale | Chief Medical Officer | 38,679 0.0149% | $3.06 | $118,346 | -16.94% | ||
| 2021-09-13 | Sale | Chairman and CEO | 82,107 0.0357% | $6.50 | $533,696 | -56.93% | ||
| 2021-09-10 | Sale | PFO & PAO | 11,120 0.0047% | $6.50 | $72,280 | -57.69% | ||
| 2020-06-17 | Sale | 10 percent owner | 283,840 0.1709% | $3.66 | $1.04M | +4.04% | ||
| 2020-06-16 | Sale | 10 percent owner | 144,160 0.0877% | $3.66 | $528,015 | +4.63% | ||
| 2020-06-15 | Sale | 10 percent owner | 384,025 0.2247% | $3.57 | $1.37M | +3.05% | ||
| 2020-06-12 | Sale | 10 percent owner | 9,100 0.0055% | $3.58 | $32,556 | +6.30% | ||
| 2020-06-11 | Sale | 10 percent owner | 183,875 0.1139% | $3.77 | $692,786 | +3.20% | ||
| 2017-12-12 | Sale | Chief Legal Officer | 16,716 0.0174% | $3.46 | $57,842 | -16.91% | ||
| 2017-12-12 | Sale | VP, Finance | 11,220 0.0117% | $3.46 | $38,836 | -16.91% | ||
| 2017-12-12 | Sale | Chief Commercial Officer | 7,424 0.0077% | $3.46 | $25,691 | -16.91% | ||
| 2017-12-12 | Sale | Chief Communications Officer | 7,022 0.0073% | $3.46 | $24,304 | -16.91% | ||
| 2017-12-12 | Sale | Chief Technology Officer | 13,092 0.0137% | $3.46 | $45,302 | -16.91% | ||
| 2017-10-30 | Chairman & CEO | 80,776 0.0835% | $3.61 | $291,706 | -2.11% | |||
| 2017-10-27 | Chairman & CEO | 119,224 0.1159% | $3.51 | $418,524 | -5.18% | |||
| 2017-04-12 | Chairman & CEO | 58,912 0.0604% | $3.29 | $194,109 | +18.52% | |||
| 2017-04-10 | Chairman & CEO | 141,088 0.1464% | $3.37 | $474,930 | +16.21% | |||
| 2017-02-14 | 10 percent owner | 20M 29.1662% | $6.00 | $120M | -14.32% |
Insider Historical Profitability
| ARMEN GARO H | See Remarks | 625969 2.6684% | $2.83 | 26 | 6 | +16.59% |
| INCYTE CORP | 10 percent owner | 16972968 72.3519% | $2.83 | 1 | 5 | <0.0001% |
| WIINBERG ULF | director | 124063 0.5289% | $2.83 | 2 | 0 | <0.0001% |
| Sharp Shalini | director | 81311 0.3466% | $2.83 | 2 | 15 | +24.13% |
| HATSOPOULOS JOHN | director | 65000 0.2771% | $2.83 | 3 | 0 | +179.69% |
Institutional Investor Ownership
| The Vanguard Group | $19.95B | 163.82 | 34.4M | +13.66% | +$2.4B | 0.37 | |
| Deep Track Capital Lp | $18.38B | 150.95 | 31.7M | 0% | +$0 | 84.33 | |
| Point72 Asset Management | $17.47B | 143.4 | 30.11M | +151.26% | +$10.51B | 25.54 | |
| BlackRock | $16.96B | 139.29 | 29.25M | -9.27% | -$1.73B | 0.37 | |
| Artal Group S A | $9.07B | 74.44 | 15.63M | 0% | +$0 | 39.62 |